Cargando…

Plasmatic Magnesium Deficiency in 101 Outpatients Living with Type 2 Diabetes Mellitus

(1) Background: Magnesium deficiency is usually associated with type 2 diabetes mellitus (T2DM). Individuals living with T2DM with hypomagnesemia show a more rapid disease progression and have an increased risk for diabetes complications. (2) Methods: This is a cross-sectional and descriptive study...

Descripción completa

Detalles Bibliográficos
Autores principales: Zahra, Hajer, Berriche, Olfa, Mizouri, Ramla, Boukhayatia, Fatma, Khiari, Marwa, Gamoudi, Amel, Lahmar, Ines, Ben Amor, Nadia, Mahjoub, Faten, Zayet, Souheil, Jamoussi, Henda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8628662/
https://www.ncbi.nlm.nih.gov/pubmed/34842632
http://dx.doi.org/10.3390/clinpract11040095
_version_ 1784607040935559168
author Zahra, Hajer
Berriche, Olfa
Mizouri, Ramla
Boukhayatia, Fatma
Khiari, Marwa
Gamoudi, Amel
Lahmar, Ines
Ben Amor, Nadia
Mahjoub, Faten
Zayet, Souheil
Jamoussi, Henda
author_facet Zahra, Hajer
Berriche, Olfa
Mizouri, Ramla
Boukhayatia, Fatma
Khiari, Marwa
Gamoudi, Amel
Lahmar, Ines
Ben Amor, Nadia
Mahjoub, Faten
Zayet, Souheil
Jamoussi, Henda
author_sort Zahra, Hajer
collection PubMed
description (1) Background: Magnesium deficiency is usually associated with type 2 diabetes mellitus (T2DM). Individuals living with T2DM with hypomagnesemia show a more rapid disease progression and have an increased risk for diabetes complications. (2) Methods: This is a cross-sectional and descriptive study in the National Institute of Nutrition and Food Technology of Tunis in Tunisia, including all adult outpatients (≥18 years old) with a diagnosis of T2DM from 1 September 2018 to 31 August 2019. The aim of this study was to evaluate the prevalence of plasmatic magnesium deficiency in a Tunisian population of T2DM and to study the relationship between magnesium status and intake, glycemic control and long-term diabetes-related complications. (3) Results: Among the 101 T2DM outpatients, 13 (12.9%) presented with a plasmatic magnesium deficiency. The mean age was 56 ± 7.9 years with a female predominance (62%, n = 63). The mean of the plasmatic magnesium level was 0.79 ± 0.11 mmol/L (0.5–1.1), and the mean of 24 h urinary magnesium excretion was 87.8 ± 53.8 mg/24 h [4.8–486.2]. HbA1c was significantly higher in the plasmatic magnesium deficiency group than the normal magnesium status group (10% ± 1.3 vs. 8.3% ± 1.9; p = 0.04), with a significant difference in participants with a poor glycemic control (HbA1c > 7%) (100%, n = 13/13 vs. 53%, n = 47/88; p = 0.001). A weak negative relationship was also found between plasmatic magnesium and HbA1c (r = −0.2, p = 0.03). Peripheral artery disease was more commonly described in individuals with low plasmatic magnesium levels than in individuals with normal levels (39%, n = 5 vs. 0%, n = 0; p < 0.001). The mean plasmatic magnesium level in participants without diabetic nephropathy and also peripheral artery disease was significantly higher compared to individuals with each long-term diabetes-related complication (0.8 mmol/L ± 0.1 vs. 0.71 mmol/L ± 0.07; p = 0.006) and (0.8 mmol/L ± 0.1 vs. 0.6 mmol/L ± 0.08; p < 0.001), respectively. (4) Conclusions: Hypomagnesemia was identified in individuals with T2DM, causing poor glycemic control and contributing to the development and progression of diabetes-related microvascular and macrovascular complications.
format Online
Article
Text
id pubmed-8628662
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86286622021-11-30 Plasmatic Magnesium Deficiency in 101 Outpatients Living with Type 2 Diabetes Mellitus Zahra, Hajer Berriche, Olfa Mizouri, Ramla Boukhayatia, Fatma Khiari, Marwa Gamoudi, Amel Lahmar, Ines Ben Amor, Nadia Mahjoub, Faten Zayet, Souheil Jamoussi, Henda Clin Pract Article (1) Background: Magnesium deficiency is usually associated with type 2 diabetes mellitus (T2DM). Individuals living with T2DM with hypomagnesemia show a more rapid disease progression and have an increased risk for diabetes complications. (2) Methods: This is a cross-sectional and descriptive study in the National Institute of Nutrition and Food Technology of Tunis in Tunisia, including all adult outpatients (≥18 years old) with a diagnosis of T2DM from 1 September 2018 to 31 August 2019. The aim of this study was to evaluate the prevalence of plasmatic magnesium deficiency in a Tunisian population of T2DM and to study the relationship between magnesium status and intake, glycemic control and long-term diabetes-related complications. (3) Results: Among the 101 T2DM outpatients, 13 (12.9%) presented with a plasmatic magnesium deficiency. The mean age was 56 ± 7.9 years with a female predominance (62%, n = 63). The mean of the plasmatic magnesium level was 0.79 ± 0.11 mmol/L (0.5–1.1), and the mean of 24 h urinary magnesium excretion was 87.8 ± 53.8 mg/24 h [4.8–486.2]. HbA1c was significantly higher in the plasmatic magnesium deficiency group than the normal magnesium status group (10% ± 1.3 vs. 8.3% ± 1.9; p = 0.04), with a significant difference in participants with a poor glycemic control (HbA1c > 7%) (100%, n = 13/13 vs. 53%, n = 47/88; p = 0.001). A weak negative relationship was also found between plasmatic magnesium and HbA1c (r = −0.2, p = 0.03). Peripheral artery disease was more commonly described in individuals with low plasmatic magnesium levels than in individuals with normal levels (39%, n = 5 vs. 0%, n = 0; p < 0.001). The mean plasmatic magnesium level in participants without diabetic nephropathy and also peripheral artery disease was significantly higher compared to individuals with each long-term diabetes-related complication (0.8 mmol/L ± 0.1 vs. 0.71 mmol/L ± 0.07; p = 0.006) and (0.8 mmol/L ± 0.1 vs. 0.6 mmol/L ± 0.08; p < 0.001), respectively. (4) Conclusions: Hypomagnesemia was identified in individuals with T2DM, causing poor glycemic control and contributing to the development and progression of diabetes-related microvascular and macrovascular complications. MDPI 2021-10-27 /pmc/articles/PMC8628662/ /pubmed/34842632 http://dx.doi.org/10.3390/clinpract11040095 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Zahra, Hajer
Berriche, Olfa
Mizouri, Ramla
Boukhayatia, Fatma
Khiari, Marwa
Gamoudi, Amel
Lahmar, Ines
Ben Amor, Nadia
Mahjoub, Faten
Zayet, Souheil
Jamoussi, Henda
Plasmatic Magnesium Deficiency in 101 Outpatients Living with Type 2 Diabetes Mellitus
title Plasmatic Magnesium Deficiency in 101 Outpatients Living with Type 2 Diabetes Mellitus
title_full Plasmatic Magnesium Deficiency in 101 Outpatients Living with Type 2 Diabetes Mellitus
title_fullStr Plasmatic Magnesium Deficiency in 101 Outpatients Living with Type 2 Diabetes Mellitus
title_full_unstemmed Plasmatic Magnesium Deficiency in 101 Outpatients Living with Type 2 Diabetes Mellitus
title_short Plasmatic Magnesium Deficiency in 101 Outpatients Living with Type 2 Diabetes Mellitus
title_sort plasmatic magnesium deficiency in 101 outpatients living with type 2 diabetes mellitus
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8628662/
https://www.ncbi.nlm.nih.gov/pubmed/34842632
http://dx.doi.org/10.3390/clinpract11040095
work_keys_str_mv AT zahrahajer plasmaticmagnesiumdeficiencyin101outpatientslivingwithtype2diabetesmellitus
AT berricheolfa plasmaticmagnesiumdeficiencyin101outpatientslivingwithtype2diabetesmellitus
AT mizouriramla plasmaticmagnesiumdeficiencyin101outpatientslivingwithtype2diabetesmellitus
AT boukhayatiafatma plasmaticmagnesiumdeficiencyin101outpatientslivingwithtype2diabetesmellitus
AT khiarimarwa plasmaticmagnesiumdeficiencyin101outpatientslivingwithtype2diabetesmellitus
AT gamoudiamel plasmaticmagnesiumdeficiencyin101outpatientslivingwithtype2diabetesmellitus
AT lahmarines plasmaticmagnesiumdeficiencyin101outpatientslivingwithtype2diabetesmellitus
AT benamornadia plasmaticmagnesiumdeficiencyin101outpatientslivingwithtype2diabetesmellitus
AT mahjoubfaten plasmaticmagnesiumdeficiencyin101outpatientslivingwithtype2diabetesmellitus
AT zayetsouheil plasmaticmagnesiumdeficiencyin101outpatientslivingwithtype2diabetesmellitus
AT jamoussihenda plasmaticmagnesiumdeficiencyin101outpatientslivingwithtype2diabetesmellitus